Navigation Links
RHEI Pharmaceuticals Licenses Attental From MethaPharma (Vemedia Group) for Distribution Throughout Asia
Date:2/19/2008

- Natural Supplement for Attention-Deficit Hyperactivity Disorder in

Children Fulfills Growing Need Throughout Asia -

NEW HAVEN, Conn. and KORTRIJK, Belgium, Feb. 19 /PRNewswire/ -- RHEI Pharmaceuticals, Inc., a fully integrated specialty pharmaceuticals company focused on bringing proprietary medicines to the China market, and MethaPharma, part of then Vemedia Group, today announced that RHEI has licensed from MethaPharma the exclusive right to market and distribute Attental(R) throughout Asia. Attental is a nutraceutical currently commercially available in Europe for attention-deficit hyperactivity disorder (ADHD) in children.

"There is a great opportunity for Attental throughout Asia where parents prefer giving their children natural products versus prescription drugs," said Joos Horsten, Executive Chairman and Chief Executive Officer of RHEI. "There has been a growing awareness of ADHD in Asia as a more western diet and lifestyle is adopted. In addition, there are now several government programs in place to train doctors and teachers to better identify and treat children suffering from ADHD. RHEI will utilize its experience in pharmaceutical marketing and its network of contacts, particularly within the pediatric community, to bring this important natural remedy to the Asian market."

Attental has been proven in a randomized, double-blind, placebo controlled clinical trial to better overall motor performance and improve reading and spelling in children. The clinical trial demonstrated a significant improvement in the Conners' Teaching Rating Scale-L (CTRS-L) of 59 items describing different aspects of child behavior, as well as in the Child Behavior Checklist (CBCL) -- standard evaluation methods for ADHD.

"RHEI's approach which includes a hospital-based sales force in China that understands the scientific aspects of ADHD and can communicate the benefits of Attental, combined with their experience in direct to consumer and pharmacy-based marketing is the perfect partner to market and distribute Attental throughout Asia," said Curd Devos, Chief Executive Officer of MethaPharma. "We see tremendous growth potential for a product like Attental in the Asian market. It is estimated that 19.8 million children in China alone suffer from ADHD and as awareness of the disorder grows, we believe that by working with RHEI we will be well positioned to offer children and their parents a natural product that has been clinically proven to improve the behavior associated with ADHD."

About MethaPharma

MethaPharma was founded in 2003 and develops high quality food supplements (nutraceuticals). MethaPharma is present in the Belgian market since 2005 with glucosamine-products such as Osteoplus, Glucactiv and Chondractiv for a fluid articulation. After some time, Benypro was launched for the prostate and Attental for ADHD (Attention Deficit Hyperactivity Disorder), dyslexia and concentration problems. MethaPharma is now part of the Vemedia group. For more information see http://www.vemediapharma.com.

About RHEI Pharmaceuticals

RHEI Pharmaceuticals is a venture backed specialty pharmaceutical company with operations in Belgium, the U.S. and China that acquires, licenses, develops and commercializes in China proprietary drug therapies based upon the unmet needs of the emerging China pharmaceuticals market. RHEI leverages its proprietary and extensive network of experienced clinical development and regulatory professionals in China to expedite approvals for pharmaceuticals new to the China market. RHEI's growing sales and marketing capabilities then provide broad patient access in China to these new and critically necessary therapeutics. RHEI specializes in hospital-based proprietary products with a therapeutic focus on urgent unmet needs in the areas of cancer, cardiovascular disease, diabetes, neurology, and other life threatening conditions.


'/>"/>
SOURCE RHEI Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Onyx Pharmaceuticals Announces a Teleconference and Webcast to Provide an Update on Nexavar; Previously Announced Fourth Quarter and Full Year 2007 Financial Results Teleconference Rescheduled
2. NUCRYST Pharmaceuticals announces year-end results
3. Renhuang Pharmaceuticals, Inc. Retains CCG Elite
4. MiddleBrook Pharmaceuticals Engages Morgan Stanley in Its Strategic Process
5. Watson Pharmaceuticals Announces FDA Inspection of Florida Facilities
6. American Association of Clinical Endocrinologists and North American Menopause Society Fail to Disclose Financial Ties to Wyeth Pharmaceuticals
7. MedThink Communications Selected by Salix Pharmaceuticals to Launch New Product
8. Cogentus Pharmaceuticals Names Scientific Steering Committee for Global Phase 3 Clinical Program
9. Memory Pharmaceuticals Appoints Vaughn M. Kailian Interim President & Chief Executive Officer
10. Transcept Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
11. Lotus Pharmaceuticals, Inc. Implements Environmentally-friendly Cost Saving Strategies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... , ... June 25, 2016 , ... Austin residents seeking ... American College of Mohs Surgery and to Dr. Russell Peckham for medical and surgical ... effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by ...
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/24/2016)... ... , ... A recent article published June 14 on E Online ... on to state that individuals are now more comfortable seeking to undergo not only ... calf and cheek reduction. The Los Angeles area medical group, Beverly Hills Physicians (BHP) ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... and Scientific Sessions in Dallas that it will receive two significant new grants ... grants came as PHA marked its 25th anniversary by recognizing patients, medical professionals ...
(Date:6/24/2016)... ... 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, join ... wage raise to $12 an hour by 2020 and then adjusting it yearly to increase ... of the minimum wage, assure the wage floor does not erode again, and make future ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the ... 2016 - Forecast to 2022" report to their offering. ... up to date financial data derived from varied research sources ... with potential impact on the market during the next five ... comprises of sub markets, regional and country level analysis. The ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
(Date:6/23/2016)... and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of ... Farma Brasil as the company,s second affiliate in Latin America . ... ... Manager of Astellas Farma Colombia ... ...
Breaking Medicine Technology: